Cargando…
Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
Immunogenic cell death (ICD) is a form of cell death that stimulates the immune system to produce an immune response by releasing tumour-associated antigens and tumour-specific antigens and is considered to play an important role in tumour immunotherapy. In the present study, we identified two ICD-r...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241935/ https://www.ncbi.nlm.nih.gov/pubmed/37277499 http://dx.doi.org/10.1038/s41598-023-35745-w |
_version_ | 1785054101550137344 |
---|---|
author | Zong, Yuan Cao, Yu Zhang, Ding Guan, Xiaoqing Zhang, Fengyi Shen, Zhubin Yin, Fei |
author_facet | Zong, Yuan Cao, Yu Zhang, Ding Guan, Xiaoqing Zhang, Fengyi Shen, Zhubin Yin, Fei |
author_sort | Zong, Yuan |
collection | PubMed |
description | Immunogenic cell death (ICD) is a form of cell death that stimulates the immune system to produce an immune response by releasing tumour-associated antigens and tumour-specific antigens and is considered to play an important role in tumour immunotherapy. In the present study, we identified two ICD-related subtypes in osteosarcoma (OS) by consensus clustering. The ICD-low subtype was associated with favourable clinical outcomes, abundant immune cell infiltration, and high activity of immune response signalling. We also established and validated an ICD-related prognostic model, which could not only be used to predict the overall survival of OS patients but was also found to be closely related to the tumour immune microenvironment of OS patients. Overall, we established a new classification system for OS based on ICD-related genes, which can be used to predict the prognosis of OS patients and to select appropriate immunotherapy drugs. |
format | Online Article Text |
id | pubmed-10241935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102419352023-06-07 Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma Zong, Yuan Cao, Yu Zhang, Ding Guan, Xiaoqing Zhang, Fengyi Shen, Zhubin Yin, Fei Sci Rep Article Immunogenic cell death (ICD) is a form of cell death that stimulates the immune system to produce an immune response by releasing tumour-associated antigens and tumour-specific antigens and is considered to play an important role in tumour immunotherapy. In the present study, we identified two ICD-related subtypes in osteosarcoma (OS) by consensus clustering. The ICD-low subtype was associated with favourable clinical outcomes, abundant immune cell infiltration, and high activity of immune response signalling. We also established and validated an ICD-related prognostic model, which could not only be used to predict the overall survival of OS patients but was also found to be closely related to the tumour immune microenvironment of OS patients. Overall, we established a new classification system for OS based on ICD-related genes, which can be used to predict the prognosis of OS patients and to select appropriate immunotherapy drugs. Nature Publishing Group UK 2023-06-05 /pmc/articles/PMC10241935/ /pubmed/37277499 http://dx.doi.org/10.1038/s41598-023-35745-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zong, Yuan Cao, Yu Zhang, Ding Guan, Xiaoqing Zhang, Fengyi Shen, Zhubin Yin, Fei Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma |
title | Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma |
title_full | Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma |
title_fullStr | Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma |
title_full_unstemmed | Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma |
title_short | Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma |
title_sort | immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241935/ https://www.ncbi.nlm.nih.gov/pubmed/37277499 http://dx.doi.org/10.1038/s41598-023-35745-w |
work_keys_str_mv | AT zongyuan immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma AT caoyu immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma AT zhangding immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma AT guanxiaoqing immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma AT zhangfengyi immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma AT shenzhubin immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma AT yinfei immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma |